Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized add-on Trial of D-serine for Depression

To see complete record on, please visit this link

Id: NCT04721249

Organisation Name: Psychiatric Hospital of the University of Basel

Overal Status: Recruiting

Start Date: July 1, 2021

Last Update: July 28, 2021

Lead Sponsor: André Schmidt

Brief Summary: The glutamate system is emerging as target for the development of novel antidepressant medication, in particular compounds modulating the NMDA receptor. While the NMDA receptor antagonist ketamine is an effective option for many treatment-restistant patients, it is also accompanied by dissociative and cognitive effects and also bears the risk to develop addiction, side effects that are significantly restricting its clinical utility. There is now compelling evidence of the antidepressant potential of D-serine, a NMDAR co-agonist. Compared to ketamine, D-serine goes along without any psychotomimetic effects or other side effects and thus might be a prom-ising novel antidepressant.

This study represents the first randomized control trial to test the efficacy of D-serine as an adjuvant therapy in patients with depression and thereby adds to re-cent efforts to establish novel glutamatergic antidepressants. Besides clinical measures, this study also explores the biological mechanisms underlying D-serine's clinical effect.

  • Major Depressive Disorder

Total execution time in seconds: 0.176265001297